The Journal of the Pharmacy Society of Wisconsin
  • Home
  • Past Issues
    • Journal Archives
    • JPSW 2023
    • JPSW 2022
    • JPSW 2021
    • JPSW 2020
    • JPSW 2019
    • JPSW 2018
    • JPSW 2017
  • JPSW Supplements
  • For Authors and Reviewers
    • Author Guidelines
    • CE Author Guidelines
    • Case Report Author Guidelines
    • Types of Manuscripts
    • Peer Review Information
    • Emerging Writers Course
    • Editorial Plans
    • Submit a Manuscript
  • Open-Access Series
    • Preceptor Development Series
    • Statistics Review Series
  • About
    • Advertise in The Journal
    • Editorial Advisory Committee
  • Contact

Beyond Dopamine and Tablets: Investigational and Newly Approved Antipsychotics for Treating Schizophrenia 

by Kevin M. Bozymski, PharmD, BCPS, BCPP, Asia I. Mian, 2021 PharmD Candidate, Thomas Ringsred, 2021 PharmD Candidate, Eric Ripley, 2021 PharmD Candidate, Isabelle M. Sviatoslavsky, 2021 PharmD Candidate 

"Objectives: To review the pharmacology, dosing/administration, efficacy, safety, and applicable costs of novel antipsychotics and formulations approved since 2018 or currently under investigation for the treatment of schizophrenia.
Methods: A PubMed search (2010 to November 2020) was conducted using the search terms schizophrenia, asenapine, evenamide, lumateperone, olanzapine, paliperidone, risperidone, roluperidone, samidorphan, ALKS 3831, HP-3070, ISM, ITI-007, LY03004, MIN-101, NW-3509, and PP6M. Additional data were obtained from references
of identified articles, drug information databases, manufacturer product labeling and websites, and Clinicaltrials.gov.
Results: Two novel antipsychotic formulations have been approved (risperidone extended-release [ER] subcutaneous injection in July 2018, and asenapine transdermal patch in October 2019), with 2 risperidone
ER intramuscular injections and 1 paliperidone ER intramuscular injection under investigation. One novel antipsychotic has been approved (lumateperone tosylate oral capsule in December 2019), with 3 additional drugs at least nearing phase 3 clinical trials: samidorphan (in combination with olanzapine to mitigate weight gain), roluperidone (for negative symptoms of schizophrenia), and evenamide (as an adjunctive agent for positive symptoms of schizophrenia).

Conclusions: As antipsychotic non-adherence increases risk of schizophrenia relapse, investigators have continued developing several novel molecules and non-oral formulations over the past few years that aim to solve existing efficacy gaps and minimize adverse effects. Due to the significant costs associated with these new treatments, pharmacists should be prepared to guide mental health professionals and educate patients on their efficacy, safety, and administration concerns relative to established antipsychotic treatments for schizophrenia."


Keywords:  Antipsychotic Agents, Paliperidone Palmitate, Risperidone, Olanzapine, Injections, Intramuscular, Asenapine, Schizophrenia, 3-carboxamido-4-hydroxynaltrexone, Transdermal Patch, Mental Health, Pharmacists, Product Labeling, Injections, Subcutaneous, Recurrence, Pharmaceutical Preparations

Download PDF 

2021 March/April Table of Contents 

The Journal of the Pharmacy Society of Wisconsin


Past Issues

2020
2021
​2022
2019
2018
2017

About PSW

www.pswi.org

Contact Us

thejournal@pswi.org
  • Home
  • Past Issues
    • Journal Archives
    • JPSW 2023
    • JPSW 2022
    • JPSW 2021
    • JPSW 2020
    • JPSW 2019
    • JPSW 2018
    • JPSW 2017
  • JPSW Supplements
  • For Authors and Reviewers
    • Author Guidelines
    • CE Author Guidelines
    • Case Report Author Guidelines
    • Types of Manuscripts
    • Peer Review Information
    • Emerging Writers Course
    • Editorial Plans
    • Submit a Manuscript
  • Open-Access Series
    • Preceptor Development Series
    • Statistics Review Series
  • About
    • Advertise in The Journal
    • Editorial Advisory Committee
  • Contact